Glide Tablet contains Glipizide 5 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, indicated for the management of type 2 diabetes mellitus. It functions primarily by stimulating pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Glide is prescribed as an adjunct to diet and exercise to improve glycemic control in patients inadequately controlled by lifestyle modifications alone. The onset of action typically occurs within 30 minutes to 1 hour, with peak effects observed between 1 to 3 hours post-administration. Dosage should be individualized based on the patient’s glycemic response, with careful monitoring to minimize the risk of hypoglycemia, a common adverse effect. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in type 1 diabetes, diabetic ketoacidosis, and during pregnancy or lactation. Patients should be educated on recognizing symptoms of hypoglycemia and advised to maintain regular meal patterns. Glide Tablet should be used under medical supervision, with periodic assessment of blood glucose and HbA1c levels to optimize therapeutic outcomes. Drug interactions may occur with agents such as beta-blockers, corticosteroids, and diuretics, necessitating close monitoring. Overall, Glide Tablet is an effective option for improving glycemic control in type 2 diabetes when used appropriately.